The combining of tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for advanced stage hepatocellular carcinoma

HIGHLIGHTS

• who: Shou-Wu Lee et al. from the Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan Department of Internal Medicine, Shan Medical University, Taichung, Taiwan have published the article: The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma, in the Journal: (JOURNAL) of 18/08/2022
• what: The aim of this study is to generate real-world data on patients with advancedstage HCC that have received a combination of TKIs and ICIs as first-line therapy. Although the study showed . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.